Pfizer grabs osteoarthritis therapy in $250M deal

Pfizer has once again demonstrated its zeal for biotech, inking a $250 million deal to in-license the worldwide rights to an experimental osteoarthritis therapy under development at Germany's Scil Technology. Scil has been developing a cartilage specific growth factor--CD-RAP--to regenerate tissue in degenerative joints. The companies didn't break out how the $250 million in potential rewards will be split among upfront fees and milestone payments.

"This partnership reflects Pfizer's ongoing commitment to pursue the best science anywhere on the globe and secure novel technologies and products that will complement our existing research programs," said Dr. Edmund Harrigan, senior vice president worldwide business development.

- here's Pfizer's release
- read the AP report

Related Articles:
A look inside Pfizer's biotech center. Report
Speculation soars over Pfizer's interest in biotech. Report
Pfizer hires new R&D chief, launches biotech center. Report
Pfizer's future rests with biotech. Report
Pfizer to invest $50M in biotech start-ups. Report

Suggested Articles

Bluebird Bio offered the first glimpse of how its CAR-T follow-up is working in multiple myeloma patients who have tried several other treatments.

Zentalis is coming out of stealth with an $85 million series C, which will propel its lead programs into pivotal trials and broaden its pipeline.

The planned takeover centers on ARQ 531, a BTK inhibitor that triggered durable responses in patients with B-cell malignancies.